Search results

  1. D

    The Observer/Guardian article: Does the microbiome hold the key to chronic fatigue? About patient led 'research' group Remission Biome.

    Well, sure, maybe. Depending on what you're looking for and the diagnostic, certainty can be hard to nail down. Regardless, I am no fan of long-term abx, at least not for me.
  2. D

    Typing myalgic encephalomyelitis by infection at onset: A DecodeME study, 2023, Bretherick et al

    Perhaps more individuals being told more recently they test negative to a wider array of pathogens, as more are being tested for? Since many diagnostics flat out suck, some of those reporting no infectious onset, or they do not know, may simply have been incorrectly informed - which would change...
  3. D

    Post-exertional malaise in daily life and experimental exercise models in patients with [ME/CFS], 2023, Vøllestad and Mengshoel

    I agree with everything you've said here @Andy . I was in an ME/CFS study once a few years back that in part tried to assess PEM through two CPETs and fMRIs. I was in a hospital for the testing four days, if I recall correctly. Blood work drawn every few hours for those four days and nights...
  4. D

    CDC Data Brief: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022, 2023, Vahratian, Unger et al

    "Have you ever been told by a doctor that you have CFS or ME?" is not really meaningful. You think most doctors - or other "health professionals" - in the US understand what to look for? This was a garbage diagnosis 30 years ago, and it remains a garbage diagnosis for most clinicians - who were...
  5. D

    CDC Data Brief: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022, 2023, Vahratian, Unger et al

    I wouldn't be surprised if this, if accurate, is more peculiar to the US than some other countries, and reflects the folding in of many vector-borne diseases.
  6. D

    CDC Data Brief: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022, 2023, Vahratian, Unger et al

    Doesn't sound like anything much to be concerned about if I'm an uninformed clinician. Especially the "and other symptoms" part. Or the "activity-limiting fatigue" for that matter. So, Deliverance types. Reckon tending stills and picking banjos instead of working for a living.
  7. D

    Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study 2023 Vrijmoeth, Knoop et al

    Enough of them know better. It's not all blind filial chanting. Although this study comes close, in my estimation. If you research Lyme, truly study its landscape for a long time, you realize there are no pat answers yet about persistence. That is criminal after more than 40 years. It's a...
  8. D

    Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study 2023 Vrijmoeth, Knoop et al

    Studies like this don't seem for me to be so much about science as they do churning out party-line rhetoric. Anybody here who's familiar with typical Lyme symptoms, check out Table 2 Baseline Patient Characteristics and see if that might be coming up short. And what does this even mean...
  9. D

    Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study 2023 Vrijmoeth, Knoop et al

    The primary determinant should be having clinically demonstrated LB. If you're going to talk causes of persistent symptoms, first order of business is being able to prove, unconditionally, Lyme and/or its co-infections (which can cause similar sequelae) have been eradicated - this in order to...
  10. D

    Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study 2023 Vrijmoeth, Knoop et al

    "No evidence was found for microbiological or LB-specific clinical determinants of persistent symptoms, but an association of host immune responses with persistent symptoms was observed." No evidence at all? None? With close to 300 Lyme patients? I'd have thought there might be some somewhere...
  11. D

    Trial Report The economic burden of myalgic encephalomyelitis/chronic fatigue syndrome in Australia, 2023, Zhao

    Whatever happened to "Opportunity cost is the highest valued opportunity lost"? I'd hope to see a stab at that in any meaningful estimate. The lost potential never realized.
  12. D

    US: Announcement of Intent To Establish Federal Advisory Committee on Long COVID

    They may be able to learn from CFSAC's story.
  13. D

    Preprint IgG Antibody Responses to Epstein-Barr Virus in ME/CFS:Their Effective Potential for Disease Diagnosis & Pathological Antigenic Mimicry, 2023, Fonseca

    I confess I am a bit bemused by the broad indifference to IgG values that characterizes the greater medical community. It is my simple and arguably simplistic understanding that when infected, the body's first defensive response is IgMs. This lasts roughly 30 days. It can involve fever and...
  14. D

    Quantitative susceptibility mapping at 7 Tesla in COVID-19: mechanistic and outcome associations, 2023, Rua et al.

    I'd be lucky to get a 3T. When I tested normal with an MRI, it was with 1.5T. The times my MRI came out funky was with a 3T. If I had access to a 7T, I'd do whatever I could to see its results.
  15. D

    Preprint Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms & Patient Experiences After Covid-19 Immunization, 2023, Krumholz, Iwasaki +

    Depending on where one lives, there may have been many who were not really surprised. North central US, northeast US, west coast US...There, at least, there'd been precedent of sorts. Too often, this is what medicine is these days.
  16. D

    Opinions on payments to participants in research

    I've participated in several research studies. Back then, being paid helped with my decision to participate, but it wasn't necessary. I'm sicker today. Arguably a bit more cynical as well; at the very least, more practical. If I knew the researcher and liked them, I'd do it without pay, but of...
  17. D

    USA: National Institutes of Health (NIH) intramural ME/CFS study

    Bloodwork and CSF, correct? Pretty good for acute infections. Even then, though, the metrics or diagnostics may be problematic depending on the infection. As for persistent infections, those lasting months or years, I'm not sure how strong we are at identifying them; that hasn't been our medical...
  18. D

    USA: Mount Sinai PACS clinic and Dr David Putrino

    Not sure why Lyme is in the mix then. Well, chronic Lyme as they are referring to it. A good portion of whomever they see with a history of Lyme will still clinically present as Lyme, e.g, CDC-positive Bb IgG's. But, eh, it's nice to be included.
  19. D

    Guardian: Private UK health data donated for medical research shared with insurance companies (UK Biobank)

    Whoa! If true in the US as well, the implications to people like me could be bad. That has to be illegal if they said it would be shared with no one. Tiered pricing, with some folks not allowed coverage? Folks like us?
Back
Top Bottom